Women Who Use ADHD Meds: A Growing Group

ADHD medication use among reproductive-age women increased dramatically

(RxWiki News) The number of women who take medication for attention deficit hyperactivity disorder (ADHD) has sharply increased in recent years, according to the Centers for Disease Control and Prevention (CDC).

The CDC reported a 700 percent increase in the use of ADHD medications among women between the ages of 25 and 29. Women between the ages of 30 and 34 saw an increase of 560 percent.

The agency looked at prescription claim data for each year from 2003 through 2015 and found that ADHD medicine prescriptions increased for all included women's age groups and in all US geographic regions.

According to the claim data, the most commonly filled ADHD medicines among this group of women were mixed amphetamine salts (Adderall), lisdexamfetamine (Vyvanse) and methylphenidate (Ritalin) — all stimulants.

Stimulants treat ADHD by changing the amounts of certain natural substances in the brain. Stimulants are controlled substances (in the Schedule II category) because they pose a high risk of abuse and dependence.

The CDC report pointed out that reproductive-age women were filling more and more ADHD prescriptions. And with little information available about the safety of taking ADHD medicine during pregnancy, the CDC recommended that women who are pregnant or thinking about becoming pregnant talk with their health care providers about all medicines they take.

“Half of all pregnancies in the United States are unplanned, and women may be taking prescription medicine early in pregnancy before they know they are pregnant," said Dr. Coleen Boyle, director of the CDC's National Center on Birth Defects and Developmental Disabilities, in a press release. "Early pregnancy is a critical time for the developing baby. We need to better understand the safest ways to treat ADHD before and during pregnancy.”

This report was recently published in the CDC's Morbidity and Mortality Weekly Report.

Written By Anyssa Garza, PharmD, BCMAS